Difference between revisions of "Example orders for Docetaxel (Taxotere) in prostate cancer"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "once 30 minutes prior" to "once, 30 minutes prior")
m (Text replacement - ", 30 minutes prior" to " - 30 minutes prior")
Line 16: Line 16:
 
====Supportive medications====
 
====Supportive medications====
 
*[[Dexamethasone (Decadron)]] 8 mg PO given twice, the evening before and morning of chemotherapy
 
*[[Dexamethasone (Decadron)]] 8 mg PO given twice, the evening before and morning of chemotherapy
*[[Dexamethasone (Decadron)]] 12 mg PO once, 30 minutes prior to chemotherapy
+
*[[Dexamethasone (Decadron)]] 12 mg PO once - 30 minutes prior to chemotherapy
*Diphenhydramine (Benadryl) 25 to 50 mg IV once, 30 minutes prior to chemotherapy
+
*Diphenhydramine (Benadryl) 25 to 50 mg IV once - 30 minutes prior to chemotherapy
*Famotidine (Pepcid) 20 mg IV over 15 minutes once, 30 minutes prior to chemotherapy
+
*Famotidine (Pepcid) 20 mg IV over 15 minutes once - 30 minutes prior to chemotherapy
  
 
Hydration:
 
Hydration:
Line 35: Line 35:
  
 
====Supportive medications====
 
====Supportive medications====
*[[Dexamethasone (Decadron)]] 10 mg IV once, 30 minutes prior to chemotherapy
+
*[[Dexamethasone (Decadron)]] 10 mg IV once - 30 minutes prior to chemotherapy
 
*Prochlorperazine (Compazine) 10 mg PO once, prior to chemotherapy
 
*Prochlorperazine (Compazine) 10 mg PO once, prior to chemotherapy
 
*Due to severe neutropenia, used: [[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 2, 24 hours after completion of chemotherapy
 
*Due to severe neutropenia, used: [[Pegfilgrastim (Neulasta)]] 6 mg SC once on day 2, 24 hours after completion of chemotherapy

Revision as of 02:43, 11 July 2019


Remember that example order sets that may contain additional information about supportive medications, suggestions for monitoring, hydration, and pre-treatment screening information for chemotherapy regimens are purely anecdotal, provided only as examples of what some other providers may be using, and are typically not based on references in the primary literature.


Docetaxel (Taxotere)

Published regimens and references can be found on the prostate cancer page.

Example order set #1

21-day cycles

Supportive medications

  • Dexamethasone (Decadron) 8 mg PO given twice, the evening before and morning of chemotherapy
  • Dexamethasone (Decadron) 12 mg PO once - 30 minutes prior to chemotherapy
  • Diphenhydramine (Benadryl) 25 to 50 mg IV once - 30 minutes prior to chemotherapy
  • Famotidine (Pepcid) 20 mg IV over 15 minutes once - 30 minutes prior to chemotherapy

Hydration:

  • Normal saline IV continuous infusion at 5 mL/H
  • Normal saline 25 to 50 mL IV prn flush before and after chemotherapy

Nursing:

  • Patients without central lines: insert peripheral IV before therapy. Flush peripheral IV with 10 mL 0.9% normal saline after each day's dose of chemotherapy. Remove peripheral IV when therapy is complete.
  • Patients with central lines: access the central venous access device before therapy. Flush central line according to institutional guidelines after each day's dose of chemotherapy. Deaccess device when therapy is complete.

Example order set #2

21-day cycles

Supportive medications

  • Dexamethasone (Decadron) 10 mg IV once - 30 minutes prior to chemotherapy
  • Prochlorperazine (Compazine) 10 mg PO once, prior to chemotherapy
  • Due to severe neutropenia, used: Pegfilgrastim (Neulasta) 6 mg SC once on day 2, 24 hours after completion of chemotherapy

Hydration:

  • Normal saline IV continuous infusion at 5 mL/H
  • Normal saline 25 to 50 mL IV prn flush before and after chemotherapy

Nursing:

  • Patients without central lines: insert peripheral IV before therapy. Flush peripheral IV with 10 mL 0.9% normal saline after each day's dose of chemotherapy. Remove peripheral IV when therapy is complete.
  • Patients with central lines: access the central venous access device before therapy. Flush central line according to institutional guidelines after each day's dose of chemotherapy. Deaccess device when therapy is complete.